Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

被引：0
|
作者：
Dan Lu
Chunze Li
Matthew Riggs
Daniel Polhamus
Jonathan French
Priya Agarwal
Shang-Chiung Chen
Shweta Vadhavkar
Monika Patre
Alexander Strasak
Angelica Quartino
Jin Yan Jin
Sandhya Girish
机构：
[1] Genentech,Department of Clinical Pharmacology
[2] Inc.,undefined
[3] Metrum Research Group,undefined
[4] F. Hoffmann-La Roche Ltd.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Trastuzumab emtansine (T-DM1); HER2; Pharmacokinetics; Previously untreated metastatic breast cancer; MARIANNE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：175 / 185
页数：10
相关论文
共 50 条
  • [31] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [32] The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence
    Giuliani, Jacopo
    Bonetti, Andrea
    BREAST JOURNAL, 2021, 27 (01): : 75 - 76
  • [33] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791
  • [34] The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
    Peipei Liu
    Jiajun Fan
    Ziyu Wang
    Wenjing Zai
    Ping Song
    Yongping Li
    Dianwen Ju
    AMB Express, 10
  • [35] Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy
    Molinelli, Chiara
    Parisi, Francesca
    Razeti, Maria Grazia
    Arecco, Luca
    Cosso, Maurizio
    Fregatti, Piero
    Del Mastro, Lucia
    Poggio, Francesca
    Lambertini, Matteo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 241 - 250
  • [36] The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
    Liu, Peipei
    Fan, Jiajun
    Wang, Ziyu
    Zai, Wenjing
    Song, Ping
    Li, Yongping
    Ju, Dianwen
    AMB EXPRESS, 2020, 10 (01)
  • [37] In vitro effects of Trastuzumab Emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells
    Mignot, F.
    Kirova, Y.
    Verrelle, P.
    Teulade-Fichou, M-P
    Megnin-Chanet, F.
    CANCER RADIOTHERAPIE, 2021, 25 (02): : 126 - 134
  • [38] Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study
    Kojima, Yasuyuki
    Yoshie, Reiko
    Kawamoto, Hisanori
    Shimo, Arata
    Uejima, Tomoko
    Iwatani, Tsuguo
    Motoyoshi, Ai
    Kanemaki, Yoshihide
    Boku, Narikazu
    Tsugawa, Koichiro
    ONCOLOGY, 2019, 96 (06) : 309 - 317
  • [39] Enhanced antitumor efficacy of T-DM1 in combination with pertuzumab in HER2-positive breast cancer models
    Sun, Yuliang
    Dey, Nandini
    Carlson, Jennifer
    Brammer, Melissa
    De, Pradip
    Leyland-Jones, Brian
    CANCER RESEARCH, 2014, 74 (19)
  • [40] Pharmacokinetics (PK) of Trastuzumab-DM1 (T-DM1) and Paclitaxel (T) in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen
    Lu, D.
    Krop, I.
    Modi, S.
    Elias, A.
    LoRusso, P.
    Huang, J.
    Lu, M.
    Girish, S.
    CANCER RESEARCH, 2010, 70
12345